Antibiotic resistance, biofilm production ability and genetic diversity of carbapenem-resistant *Pseudomonas aeruginosa* strains isolated from nosocomial infections in southwestern Iran

Reza Heidari1,2 · Ahmad Farajzadeh Sheikh1,2 · Mohammad Hashemzadeh1,2 · Zahra Farshadzadeh1,2 · Shokrollah Salmanzadeh2,3 · Morteza Saki1,2

Received: 24 November 2021 / Accepted: 2 February 2022 / Published online: 15 February 2022 © The Author(s), under exclusive licence to Springer Nature B.V. 2022

Abstract

**Background** This study was aimed to evaluate the antibiotic resistance, biofilm formation, and genetic diversity of carbapenem-resistant *Pseudomonas aeruginosa* (CRPA) strains isolated from four types of nosocomial infections (NIs) including urinary tract infection (UTI), ventilator-associated pneumonia (VAP), surgical site infection (SSI), and bloodstream infection (BSI).

**Methods and results** In total, 115 isolates of NIs-causing *P. aeruginosa* were collected from NIs. Antibiotic susceptibility testing (AST) was performed using disk diffusion method and minimum inhibitory concentrations. Biofilm formation was tested on 96-well polystyrene microtiter plates (MTP). CRPA isolates were genotyped using multiple-locus variable number of tandem repeat analysis (MLVA). The most resistance and susceptibility rates were observed to amikacin (70.6%) and colistin (96.1%), respectively. Colistin and meropenem were the most active antimicrobial agents in VAP, SSI, and BSI. While, colistin and cefepime were the most active in UTIs. In total, 52.2% (n = 60/115) of *P. aeruginosa* isolates were carbapenem resistant, of which 95.0%, 55.0%, and 5.0% were multidrug-resistant, extensively drug-resistant, and pandrug-resistant, respectively. There was a significant association between resistance to carbapenem and resistance to other antibiotics except for piperacillin/tazobactam. The biofilm production of CRPA isolates was 95.0%, of which 23.3% were strong biofilm producers. Based on MLVA, there were 34 different types of CRPA isolates classified into three main clusters and 5 sub clusters.

**Conclusion** The association of CRPA with other antibiotic resistance, the high rates of biofilm production, and the high genetic diversity of the isolates may be a warning of the need for a careful surveillance program.

**Keywords** Antibiotic resistance · Biofilm · MLVA · Nosocomial infections · *Pseudomonas aeruginosa*

Introduction

Nosocomial infections (NIs) acquired in hospitals and also known as healthcare associated infections (HCAIs), occur at 48 h after hospital admission, 3 days after discharge, or 30 days after surgery [1]. NIs associated problems with a global impact in hospital care are considered serious complications that worsen the prognosis of the underlying disease, cause a higher mortality rate, prolong the length of hospital stay, reduce the quality of patients’ life, and lead to an increase in the cost of treatment. Hence, NIs require special attention to be managed and controlled [2]. The prevalence of NIs in different regions of Iran has been reported to be 0.4–15.6% [3]. In addition, urinary tract infection (UTI) with 26.8%, ventilator-associated pneumonia (VAP) with 20.3%, surgical site infection (SSI) with 19.7%, and bloodstream infection (BSI) with 13.5% are the most common NIs in Iran [4].

*Pseudomonas aeruginosa*, a Gram-negative aerobic rod, is still considered one of the most antibiotic resistance pathogens of NIs [2]. *P. aeruginosa* accounts for 10–11%
of all NIs [2]. This bacterium with intrinsic resistance to various antimicrobial agents can easily tolerates many antibiotics including carbapenems (imipenem and meropenem) [2, 5–7]. Carbapenems have been reported to be the most effective antimicrobial agents against severe P. aeruginosa NIs and are often used as a last resort antibiotics in the treatment of bacterial infections [5, 6]. Nevertheless, overuse of antibiotics leads to the emergence of carbapenem-resistant P. aeruginosa (CRPA) strains with severe and fatal infections and increases the cost of therapy [7].

An important virulence factor for this bacterium is biofilm which is described as a set of bacterial cells coated by a polysaccharide layer [8]. Nowadays, the important role of biofilm-producing bacteria in medicine is well-recognized due to the rise of HCAIs. Also, the biofilms play a main role in antibiotic resistance owing to microorganism protection, stop or slow down the antibiotic penetration, and altered microenvironment [9, 10]. The significant association of biofilm formation with CRPA was demonstrated in a previous study [11].

Considering the important role of P. aeruginosa as a causative agent of NIs, there is a need to use molecular typing methods for infection control and epidemiological studies. Various typing methods have been used to assess the genetic diversity and distribution of P. aeruginosa in different niches [12]. One of the most efficient methods to determining and study the genotypes of different bacteria is multiple-locus variable number of tandem repeats analysis (MLVA). Effective discrimination of different P. aeruginosa genotypes using MLVA has been reported previously [13]. Since most of the loci on the agarose gel are determined by polymerase chain reaction (PCR), this technique is considered to be repeatable, economical and least time consuming [14]. The popularity of MLVA as a clonality genotyping method for hospital-based epidemiological surveys has increased in recent years [12].

To the best of our knowledge, this research is one of the few studies on molecular typing of P. aeruginosa using MLVA method in several southern cities of Iran. This study was aimed to evaluate the antibiotic resistance patterns, biofilm formation ability, and genetic diversity of CRPA strains isolated from NIs in three cities of Khuzestan province, southwest Iran.

Study design and bacterial isolates

Over a 6-month period (October 2020–March 2021), 115 NIs-causing P. aeruginosa isolates were collected from hospitalized patients referred to teaching hospitals of three cities of Khuzestan province (Ahvaz, Abadan and Khorramshahr), southwest Iran. NIs were defined according to the diagnostic criteria of the Centers for Disease Control and Prevention (CDC) [15]. The isolates were related to four types of NIs including UTI, VAP, SSI and BSI, which were collected from different wards including intensive care unit (ICU), burn, infectious diseases, nephrology, emergency, pediatrics, gastroenterology, skin diseases, dialysis, internal medicine, and critical care unit (CCU). Initial identification of the isolates was based on typical growth on a selective medium Cetrimide agar (Merck, Darmstadt, Germany) and different biochemical tests including colony characteristics, sulphur indole and motility (SIM), triple sugar iron (TSI), urease, citrate, oxidase, and growth at 42 °C [16]. PCR of the gyrB gene was used for final identification [17]. P. aeruginosa ATCC® 27,853™ was used as a positive control. A stock of all bacterial isolates was prepared in a microtube containing tryptic soy broth (TSB) with 20% glycerol and stored at −80 °C until further investigation.

Antimicrobial susceptibility testing (AST)

For antimicrobial susceptibility testing of the following antibiotics, the disk diffusion method was used according to the Clinical and Laboratory Standards Institute (CLSI) protocol: piperacillin (100 μg), piperacillin/tazobactam (100/10 μg), ceftazidime (30 μg), cefepime (30 μg), aztreonam (30 μg), tobramycin (10 μg), gentamicin (10 μg), amikacin (30 μg), and ciprofloxacin (5 μg) (MAST, Berkshire, UK) [18]. Moreover, minimum inhibitory concentrations (MICs) of imipenem, meropenem, and colistin were assayed by broth microdilution method according to CLSI instructions (18). P. aeruginosa isolates with MICs of ≥ 8 μg/ml for imipenem or/and meropenem and ≥ 4 μg/ml for colistin were described as carbapenem and colistin resistant, respectively [18]. To categorize multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR) isolates, criteria defined by Magiorakos et al. [19] were employed. P. aeruginosa ATCC® 27,853™ [Iranian Research Organization for Science and Technology (IROST), Tehran, Iran] was used as a quality control strain according to the CLSI protocol.

Materials and methods

Ethical clearance

Ethical approval was obtained from the Ethics Committee of the Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran (IR.AJUMS.REC.1399.530). Written informed consent was obtained from all patients.
In vitro biofilm assay

To assess the biofilm formation ability of *P. aeruginosa* isolates on 96-well polystyrene microtiter plates (MTP), the crystal violet staining (CVS) method was applied as previously mentioned [20]. Uninoculated Muller-Hinton broth (MHB) and *P. aeruginosa* ATCC® 27,853™ were used sequentially as negative and positive controls. The biofilm forming ability of the isolates was classified into four categories: non biofilm producer: $\text{OD}_t < \text{OD}_c$, weak biofilm producer: $\text{OD}_c < \text{OD}_t < 2 \times \text{OD}_c$, moderate biofilm producer: $2 \times \text{OD}_c < \text{OD}_t < 4 \times \text{OD}_c$ and strong biofilm producer: $\text{OD}_t \geq 4 \times \text{OD}_c$. $\text{OD}_t$ demonstrates the mean OD of the three wells for each isolate and $\text{OD}_c$ shows the mean OD of the three wells for the control [20].

MLVA analysis

Bacterial DNA was extracted by boiling method as described previously [21]. Genotyping of CRPA isolates was carried out by MLVA using primers for seven loci, including ms142, ms172, ms213, ms214, ms215, and ms217 (Table 1) [22]. First, a mixture of PCR components was prepared containing 12.5 μl of 2 × Taq Master Mix (Ampliqon, Odense, Denmark), 1 μl of 10 pM of each primer (Metabion, Steinkirchen, Germany), 5 μl of template DNA (50 ng), and double-distilled H2O to the total volume of 25 μl per reaction. The thermal reactions were produced using BIO-RAD C1000 thermal cycler (Applied Biosystems, USA) as follows: the primary denaturation for 4 min at 94 °C, followed by 32 cycles (30 s at 93 °C, 30 s at 60 °C, and 60 s at 72 °C), and the final extension phase for 4 min at 72 °C. *P. aeruginosa* strain PAO1 was used as a control for all the experiments. PCR products were loaded in 2% agarose gel and stained with safe stain (Sinaclon Co., Tehran, Iran). Then the ultraviolet gel documentation device (Protein Simple, San Jose, CA, USA) was used to observe the bands.

To determine the repeat units of each locus, the size of the flanking regions (offset size) was subtracted from the size of the PCR product to obtain the number of TRs, which is then divided to the distinction of the repeat size. The Bioinformatics 7.6 software (Applied Maths, St-Martens-Latem, Belgium) was employed to cluster the MLVA profiles using the UPGMA (Unweighted Pair Group Method with Arithmetic) method. Furthermore, BioNumerics was utilized to create similarity coefficient of Pearson’s correlation and the minimum spanning tree (MST). The dendrogram displayed the dissimilarity of the strain in accordance with the UPGMA algorithm. The Hunter-Gaston diversity index was used to determine the polymorphism index of the individual or combined VNTR loci. The strains with 80% or more similarity [based on 2 distinct VNTR loci (DLV)] were assigned to a single strain.

Statistical analysis

Statistical Package for the Social Sciences (SPSS) version 23.0 (Armonk, NY, USA) was used for statistical analysis of the data. To provide a comparison between groups, the Chi-square test or Fisher’s exact test was used. Results with $p < 0.05$ were considered significant.

Results

Clinical isolates

Sixty out of 115 (52.2%) *P. aeruginosa* isolates in our study were carbapenem resistant. Of the 115 isolates, 54.8% and 45.2% were collected from males and females, respectively. The highest and lowest rates of *P.
aeruginosa isolates were found in ICU (53.0%, n = 61) and CCU (1.7%, n = 2), respectively. The frequency of isolates in other wards was as follows: internal medicine (9.6%, n = 11), burn (9.6%, n = 11), infectious diseases (7.8%, n = 9), nephrology (3.5%, n = 4), pediatrics (3.5%, n = 4), dialysis (3.5%, n = 4), emergency (2.6%, n = 3), gastroenterology (2.6%, n = 3), and skin diseases (2.6%, n = 3). In total, 33.9% of isolates belonged to VAP type of NIs, followed by BSI (26.0%), SSI (22.6%), and UTI (17.3%). Of 60 CRPA isolates, 53.3% of them were related to women. Most CRPA isolates were obtained from ICU ward (55.0%) and the most percentage of them was related to VAP type of NIs (36.6%). The characteristics of the 60 CRPA isolates can be found in Table 2.

AST patterns

Of the 115 isolates, 60 (52.1%) and 57 (49.5%) were resistant to imipenem and meropenem, respectively. The most resistance rate was observed to amikacin (70.6%) and ciprofloxacin (65.7%). The resistance rates of other tested antibiotics were as follows: piperacillin (59.8%), ceftazidime (59.8%), aztreonam (54.9%), tobramycin (52%), gentamicin (51%), cefepime (37.9%), and piperacillin/tazobactam (42.2%). On the other hand, the most susceptibility rate was observed to colistin (96.1%). Regarding the type of NIs, colistin and meropenem were the most active antimicrobial agents in VAP, SSI, and BSI. While, colistin and cefepime were the most active in UTIs (Table 3). There was a significant association between resistance to carbapenem and resistance to other antibiotics except for piperacillin/tazobactam (p = 0.0001) (Table 4). Also, the results revealed that 95.0%, 55.0%, and 5.0% of carbapenem resistant isolates were MDR, XDR, and PDR, respectively.

In vitro biofilm assay

Of 115 P. aeruginosa isolates, 21 (18.3%), 21 (18.3%), and 61 (53.0%) isolates were strong biofilm producers, moderate biofilm producers, and weak biofilm producers, respectively. While, 12 (10.4%) of isolates were not biofilm producers. The rate of biofilm production in CRPA isolates was 95.0%, while this rate in carbapenem-susceptible P. aeruginosa (CSPA) isolates was 83.6%. Furthermore, the rates of strong and moderate biofilm formation were higher in CRPA isolates than in CSPA isolates (Table 3). Most biofilm production in CRPA isolates was related to VAP (36.6%) followed by BSI (25.0%), SSI (25.0%), and UTI (8.3%). There was a significant connection between biofilm formation and resistance to piperacillin and ceftazidime (p < 0.05).

MLVA genotyping

With regard to the amplification of seven distinct VNTR loci, the CRPA isolates were assessed by MLVA method. In general, there were 34 various MLVA types of CRPA isolates in our study which were assigned to seven main clusters, 11 subclusters, 25 singlone and nine multitone: 13 types in cluster I, three types in cluster II, six types in cluster III, eight types in cluster IV, two types in cluster V, one type in cluster VI and one type in cluster VII. The most frequent types include type 2, 6 and 28, each with three isolates (Fig. 1). According to the diversity index (hunter-gaston), the highest diversity was at VNTR loci ms142 and the lowest at VNTR loci ms223. Most of the samples belonging to cluster I showed moderate and strong biofilm formation ability. Figure 2 shows the MST patterns derived from the MLVA genotyping for the CRPA isolates. In this figure, the desired strains classified into 34 types are represented as clones based on the number of strains that were categorized. This concept is based on the association between the numbers of repetitions that were considered as comparisons in each category [46].

Discussion

P. aeruginosa is known as one of the main causes of NIs. To hinder the spread of this resistant microorganism and to take sufficient measures to prevent infections, it is necessary to monitor the susceptibility to antimicrobial agents among isolates [23]. In the present study, colistin (96.1%) showed the most susceptibility which was in line with previous studies [11, 24]. Its effectiveness can be explained by factors such as the considerable cost of colistin, its nephrotoxicity and its limited use outside hospitals [25]. Cephalosporins, carbapenems, aminoglycosides and fluoroquinolones are considered four important groups of anti-pseudomonal agents [26]. In this research, the high resistance to amikacin (70.6%) and ciprofloxacin (65.7%) was in agreement with previous studies [24, 27]. However, there were reports recommending amikacin and ciprofloxacin as effective antibiotics against nosocomial P. aeruginosa isolates [28, 29].

In this study, more than 50.0% of P. aeruginosa isolates were resistant to piperacillin (59.8%), ceftazidime (59.8%), aztreonam (54.9%), tobramycin (52.0%), and gentamicin (51.0%). These results were in line with previous reports from Nepal [8], Iran [27], and Ethiopia [28]. However, Lila et al. [30] from Kosovo and Hemmati et al. [33] from Iran reported lower resistance rates for ceftazidime and ciprofloxacin compared to our findings. These discrepancies may be due to differences in the type and race of the population studied, the source of isolates, the methods used to measure the antibiotic susceptibility, the presence or absence of
Table 2 Characteristics of 60 carbapenem-resistant *Pseudomonas aeruginosa* isolates

| Isolates | Sex | Hospital name | Hospital sector | Infection site | Biofilm formation ability | Resistance profile | Antimicrobial resistance classification | NIs type | Sex | Hospital name | Hospital sector | Infection site | Biofilm formation ability | Resistance profile | Antimicrobial resistance classification | NIs type |
|----------|-----|---------------|----------------|---------------|---------------------------|--------------------|----------------------------------------|----------|-----|---------------|----------------|---------------|---------------------------|--------------------|----------------------------------------|----------|
| 1        | Male| Emam         | ICU            | Urine         | Moderate                 | PIP TZP FEP ATM IPM MEM—GEN | XDR                     | UTI           | 10    | Male| Emam         | ICU            | Tracheal       | Strong                   | PIP FEP ATM IPM MEM—GEN | XDR                     | VAP        |
| 14       | Female| Emam   | ICU            | Blood         | Strong                   | PIP TZP FEP ATM IPM MEM—GEN | XDR                     | BSI           | 108   | Female| Golestan  | Surgery        | Tracheal       | Weak                     | PIP TZP FEP ATM IPM MEM—GEN | XDR                     | VAP        |
| 100      | Female| 17 sh  | Internal medicine | Blood    | Negative                 | PIP TZP FEP ATM IPM MEM—GEN | MDR                     | BSI           | 109   | Female| Emam       | ICU            | Tracheal       | Moderate                 | PIP TZP FEP ATM IPM MEM—GEN | XDR                     | VAP        |
| 11       | Male| Emam         | ICU            | Catheter      | Moderate                 | PIP TZP FEP ATM IPM MEM—GEN | XDR                     | VAP           | 110   | Female| Golestan  | Surgery        | Blood         | Weak                     | PIP TZP FEP ATM IPM MEM—GEN | MDR                     | BSI        |
| 111      | Male| Golestan    | CCU            | Drainage      | Moderate                 | PIP TZP FEP ATM IPM MEM—GEN | XDR                     | VAP           | 112   | Male| Golestan  | Surgery        | Blood         | Weak                     | PIP TZP FEP ATM IPM MEM—GEN | MDR                     | BSI        |
| 113      | Male| Golestan    | ICU            | Blood         | Weak                     | PIP TZP FEP ATM IPM MEM—GEN | XDR                     | BSI           | 114   | Female| Golestan  | Surgery        | Blood         | Strong                   | PIP TZP FEP ATM IPM MEM—GEN | PDR                     | BSI        |
| 12       | Female| Emam   | ICU            | Tracheal      | Moderate                 | PIP TZP FEP ATM IPM MEM—GEN | PDR                     | VAP           | 13    | Female| Emam       | Infectious diseases | Wound        | Weak                     | PIP FEP ATM IPM MEM—GEN | MDR                     | SSI        |
| 15       | Female| Emam   | Surgery        | Wound         | Weak                     | PIP TZP FEP ATM IPM MEM—GEN | XDR                     | SSI           | 18    | Female| Emam       | ICU            | Tracheal       | Weak                     | PIP FEP ATM IPM MEM—GEN | MDR                     | VAP        |
| 2        | Male| Emam         | ICU            | Blood         | Weak                     | TZP ATM IPM MEM—GEN     | XDR                     | BSI           | 20    | Female| Emam       | ICU            | Tracheal       | Weak                     | PIP TZP FEP ATM IPM MEM—GEN | XDR                     | VAP        |
| 21       | Female| Emam   | ICU            | Tracheal      | Weak                     | PIP FEP ATM IPM MEM—GEN | MDR                     | VAP           | 23    | Female| Emam       | Internal medicine | Blood        | Weak                     | PIP TZP FEP ATM IPM MEM—GEN | XDR                     | BSI        |
| 25       | Female| Emam   | Nephrology     | Wound         | Strong                   | PIP ATM IPM MEM—GEN    | MDR                     | SSI           | 26    | Female| Emam       | Internal medicine | Tracheal       | Weak                     | PIP TZP FEP ATM IPM MEM—GEN | XDR                     | VAP        |
| 31       | Male| Emam         | CCU            | Wound         | Weak                     | PIP FEP ATM IPM MEM—GEN | MDR                     | SSI           | 33    | Female| Emam       | Infectious diseases | Wound        | Strong                   | PIP TZP FEP ATM IPM MEM—GEN | XDR                     | SSI        |
| 35       | Male| Emam         | ICU            | Urine         | Moderate                 | PIP FEP ATM IPM MEM—GEN | MDR                     | UTI           | 37    | Female| Emam       | Infectious diseases | Tracheal       | Strong                   | PIP TZP FEP ATM IPM MEM—GEN | XDR                     | VAP        |
Table 2 (continued)

| Isolates | Sex | Hospital name | Hospital sector | Infection site | Biofilm formation ability | Resistance profile | Antimicrobial resistance classification | NIs type |
|----------|-----|---------------|-----------------|---------------|---------------------------|-------------------|----------------------------------------|----------|
| 40       | Female | Emam | Infectious diseases | Wound | Weak | PIP FEP ATM IPM MEM—GEN | MDR | SSI |
| 45       | Male | Emam | ICU | Tracheal | Strong | PIP TZP FEP ATM IPM MEM—GEN | XDR | VAP |
| 34       | Female | Emam | ICU | Blood | Weak | ATM IPM MEM—GEN | MDR | BSI |
| 61       | Male | Taleghani | ICU | Blood | Moderate | PIP TZP FEP ATM IPM MEM—GEN | XDR | BSI |
| 62       | Female | Taleghani | ICU | Wound | Weak | PIP FEP ATM IPM MEM—GEN | XDR | SSI |
| 63       | Male | Taleghani | Pediatric | Blood | Weak | PIP TZP FEP ATM IPM MEM—GEN | XDR | BSI |
| 64       | Female | Taleghani | ICU | Blood | Weak | PIP FEP ATM IPM MEM—GEN | XDR | BSI |
| 67       | Male | Taleghani | ICU | Blood | Moderate | PIP TZP FEP ATM IPM MEM—GEN | XDR | BSI |
| 69       | Female | Taleghani | Surgery | Wound | Weak | PIP ATM IPM MEM—GEN | XDR | SSI |
| 70       | Male | Taleghani | Pediatric | Abscess | Moderate | PIP TZP FEP ATM IPM MEM—GEN | XDR | VAP |
| 73       | Male | Taleghani | ICU | Blood | Negative | PIP—ATM IPM MEM—GEN | MDR | BSI |
| 74       | Female | Taleghani | Surgery | Biopsy | Weak | PIP TZP FEP ATM IPM MEM—GEN | XDR | SSI |
| 75       | Male | Taleghani | ICU | Blood | Weak | PIP FEP ATM IPM MEM—GEN | XDR | BSI |
| 76       | Female | Taleghani | ICU | Blood | Weak | PIP TZP FEP ATM IPM MEM—GEN | XDR | BSI |
| 77       | Male | Taleghani | ICU | Blood | Weak | PIP TZP FEP ATM IPM MEM—GEN | XDR | BSI |
| 78       | Female | Taleghani | Infectious diseases | Biopsy | Moderate | PIP FEP ATM IPM MEM—GEN | MDR | SSI |
| 79       | Female | Taleghani | Surgery | Biopsy | Weak | PIP FEP ATM IPM MEM—GEN | MDR | SSI |
| 83       | Female | Valasr | Internal medicine | Wound | Moderate | PIP TZP FEP ATM IPM MEM—GEN | XDR | SSI |
| 84       | Female | Valasr | ICU | Broncho alveolar lavage | Strong | PIP TZP FEP ATM IPM MEM—GEN | XDR | VAP |
| 85       | Female | Valasr | ICU | Broncho alveolar lavage | Weak | ATM IPM MEM—GEN | MDR | VAP |
| 87       | Male | Naft | ICU | Urine | Weak | PIP FEP ATM IPM MEM—GEN | MDR | UTI |
| 88       | Male | Naft | ICU | Tracheal | Moderate | PIP TZP FEP ATM IPM MEM—GEN | XDR | VAP |
| 9        | Male | Emam | ICU | Urine | Strong | PIP TZP FEP ATM IPM MEM—GEN | XDR | UTI |
| 92       | Male | Taleghani | Burn | Biopsy | Negative | PIP TZP FEP ATM IPM MEM—GEN | XDR | SSI |
| 94       | Male | Taleghani | Burn | Urine | Weak | PIP TZP FEP ATM IPM MEM—GEN | XDR | UTI |
Another important finding of the current research was the high resistance rate of 52.1% and 49.5% against imipenem and meropenem, respectively. In previous studies, the rate of carbapenem resistance differed greatly from 17.5% to 100.0% [11, 24, 30–33]. In this study, *P. aeruginosa* isolates in southwestern Iran showed higher rates of resistance to carbapenems than in several other countries, including China (37.2% for imipenem) [6] and Kosovo (12.5% for meropenem and 17.5% for imipenem) [30]. However, Kunwar et al. [8] from Nepal, Patel et al. [10] from India, and El-Mahdy et al. [11] from Egypt found high resistance rates (ranging from 42.5% to 100.0%) of *P. aeruginosa* to carbapenem antibiotics. In recent years, the emergence of carbapenem-resistant Gram-negative bacteria, including CRPA, has posed a new challenge in the medical field. Because the treatment of these species is associated with many problems.

antibiotic consumption surveillance programs, the presence or absence of antibiotic use surveillance in agriculture, livestock and other industries, and differences in the epidemiology of the regions.

Another important finding of the current research was the high resistance rate of 52.1% and 49.5% against imipenem and meropenem, respectively. In previous studies, the rate of carbapenem resistance differed greatly from 17.5% to 100.0% [11, 24, 30–33]. In this study, *P. aeruginosa* isolates in southwestern Iran showed higher rates of resistance to carbapenems than in several other countries, including China (37.2% for imipenem) [6] and Kosovo (12.5% for meropenem and 17.5% for imipenem) [30]. However, Kunwar et al. [8] from Nepal, Patel et al. [10] from India, and El-Mahdy et al. [11] from Egypt found high resistance rates (ranging from 42.5% to 100.0%) of *P. aeruginosa* to carbapenem antibiotics. In recent years, the emergence of carbapenem-resistant Gram-negative bacteria, including CRPA, has posed a new challenge in the medical field. Because the treatment of these species is associated with many problems.
The high resistance rates of *P. aeruginosa* isolates against carbapenems in our region indicate that the use of this group of antimicrobials need to be done with caution and as much as possible based on the results of the antibiogram test.

The assessment of resistance pattern in four types of NIs (VAP, SSI, BSI and UTI) was performed discretely and provided useful data on the effective antibiotics in each single type. Higher resistance to most antibiotics was observed in *P. aeruginosa* isolated from VAP compared to other types of NIs. In another study from Serbia, the susceptibility of VAP pathogens to common antibiotics was also low [34]. It has already been noted that the antibiotic susceptibility of *P. aeruginosa* isolates from SSI tends to be higher than that of hospital-acquired respiratory tract infections and UTIs [35]. In recent research, the antibiotic susceptibility of *P. aeruginosa* isolates from SSI to most antibiotics was higher than that of VAP and BSI except UTI. In general, studies have reported a remarkably variable frequency of drug resistant *P. aeruginosa*, which can be explained by the different study population, different site of isolation, different antibiotic used in the treatment, the severity of the disease, length of hospital stay, and methods used [1, 33].

Among the different wards, ICU (55.0%) and among NI types, VAP (36.6%) had the highest rates of CRPA isolates, respectively. These results were consistent with other studies that reported ICU admission and medical device as important risk factors for CRPA [6, 36]. In our research, 95.0% of CRPA isolates were MDR, 55.0% were XDR, and 5.0% were PDR which was noticeable and can be a threat for the future. This high rate of resistance among our isolates may be explained by the fact that they were isolated from NIs. In El-Mahdy et al. [11] study, 91.2% of CRPA isolates were MDR and there was a significant association between MDR and carbapenem resistance. In the study by Rasool et al. [37], 92.3% of CRPA isolates was XDR. According to our findings, there was a statistically significant difference in resistance rates between carbapenem-resistant and carbapenem-susceptible isolates for all tested antibiotics except piperacillin/tazobactam, as mentioned in other studies [6, 11].

In a recent study, *P. aeruginosa* isolates were evaluated in terms of biofilm production. Biofilm formation in carbapenem-susceptible and carbapenem-resistant isolates was 83.6% and 95.0%, sequentially. In the study by El-Mahdy et al. [11], biofilm production in CRPA isolates (94.0%) was higher than CSPA (65.2%) isolates. In another study by Cho et al. [38], 92.7% of CRPA isolates were biofilm producers. In the present study, *P. aeruginosa* strains isolated from VAP indicated higher biofilm production in comparison to other types of NIs. Furthermore, the rate of strong biofilm producer isolates in this type was also higher. Our results were in agreement with the study by Cepas et al. [29] in which *P. aeruginosa* isolates from respiratory samples were found to have greater biofilm formation ability than the other types [39]. There was also a close positive correlation between biofilm formation and the occurrence of VAP in the study by Uppe et al. [40]. However, the results obtained from studies by Davarzani et al. [20] and Bahador et al. [21] indicated a higher rate of strong biofilm production in urine samples than other samples. Although a higher rate of antibiotic resistance was found in biofilm-forming isolates compared to non-biofilm-forming isolates, there was only a significant association between biofilm production and resistance to piperacillin and ceftazidime ($p < 0.05$). These findings were in line with some studies that reported a significant connection between biofilm production and resistance to various antibiotics [41, 42]. Moreover, a significant association between MDR and biofilm production was observed in some studies [43, 44]. However, in some studies, no significant connection was observed between biofilm formation and resistance to individual antibiotics or MDR, suggesting that other resistance mechanisms including efflux pumps, altered outer membrane permeability, toxin/antitoxin systems, and expression of the β-lactamase resistance genes are involved [20, 26, 45].

In the present study, the MLVA typing technique with seven distinct VNTR loci was used to genetically characterize the isolated CRPA strains, resulting in the identification of 34 types. Although the MLVA method is less accurate than techniques such as pulsed-field gel electrophoresis (PFGE), because the strains are encoded based on the number of repeats in the VNTR loci, it is easy to examine the

---

**Table 4** Comparison of antibiotic resistance and biofilm production in CRPA and CSPA isolates

| Variable          | CRPA (60) | CSPA (55) | p value |
|-------------------|-----------|-----------|---------|
| Piperaclin        | 52 (86.6%)| 15 (27.3%)| 0.0001  |
| Piperaclin/tazobactam | 25 (41.6%)| 23 (41.8%)| 0.6652  |
| Cefepime          | 48 (80.0%)| 3 (5.5%)  | 0.0001  |
| Ceftazidime       | 54 (90.0%)| 15 (27.3%)| 0.0001  |
| Aztreonam         | 47 (78.3%)| 12 (21.8%)| 0.0001  |
| Gentamicin        | 47 (78.3%)| 10 (18.2%)| 0.0001  |
| Amikacin          | 54 (90.0%)| 25 (45.5%)| 0.0001  |
| Tobramycin        | 46 (76.7%)| 16 (29.1%)| 0.0001  |
| Ciprofloxacin     | 53 (88.3%)| 21 (38.2%)| 0.0001  |
| Colistin          | 4 (6.7%)  | 0 (0.0%)  | 0.0001  |

**Biofilm**

| Biofilm production | CRPA (60) | CSPA (55) | p value |
|--------------------|-----------|-----------|---------|
| Strong             | 14 (23.3%)| 7 (12.7%) |         |
| Moderate           | 13 (21.7%)| 8 (14.6%) |         |
| Weak               | 30 (50.0%)| 31 (56.4%)|         |
| Negative           | 3 (5.0%)  | 9 (16.4%) |         |

CRPA Carbapenem-resistant *Pseudomonas aeruginosa*, CSPA Carbapenem-susceptible *Pseudomonas aeruginosa*
clonal correlation of a large number of isolates [46]. In this study, most isolates belonged to cluster I followed by cluster IV and were mostly from one hospital but there was a lot of variety in sample type. According to our results, \textit{P. aeruginosa} isolates from the same medical ward had remarkably high diversity. These findings indicated that these organisms vary in genotype over time as well as within the same host [47]. Considering the high genetic diversity of CRPA isolates, which are mainly found in ICU wards, it is difficult to properly implement infection control policies. In this research, the MLVA-7 showed good results in typing of \textit{P. aeruginosa} isolates and all studied isolates were typeable. However, in a previous experiment by Lalancette et al. [48] from Canada, three not-tyable strains were detected using MLVA-7 as follows: (MS142, MS211, MS213, MS215, MS216, MS222, MS223). In another study by Johansson et al. [49] from Sweden, an agreement of 91.0% was observed between MLVA and PFGE in clone identification of \textit{P. aeruginosa} isolates from cystic fibrosis patients. Seven VNTR markers used in the study by Shokoohizadeh et al. [13] were the same as those used in our study and indicated 36 different genotypes among 72 isolates which offered a moderate discriminatory power by these VNTR markers. It is recommended that more VNTR markers be used in the future studies to evaluate their discriminatory power in determination of relatedness of circulating clones of \textit{P. aeruginosa} isolates in our region. Also, due to the spread of antibiotic resistance among bacteria causing NI, the effect of other newer antimicrobial and anti-biofilm agent (such as antimicrobial peptides) need to be evaluated in future studies.

\begin{figure}
\centering
\includegraphics[width=\textwidth]{fig1}
\caption{Clustering analysis of MLVA results of Carbapenem-resistant \textit{Pseudomonas aeruginosa} isolates using UPGMA algorithm. \textit{bl} blood, \textit{ba} broncho alveolar lavage, \textit{ca} catheter, \textit{bs} burns, \textit{wd} wound, \textit{ur} urine, \textit{tr} tracheal}
\end{figure}

Fig. 1 Clustering analysis of MLVA results of Carbapenem-resistant \textit{Pseudomonas aeruginosa} isolates using UPGMA algorithm. \textit{bl} blood, \textit{ba} broncho alveolar lavage, \textit{ca} catheter, \textit{bs} burns, \textit{wd} wound, \textit{ur} urine, \textit{tr} tracheal.
Conclusion

Carbapenem resistance in *P. aeruginosa* is indicative of a problem in NIs. Our findings showed that resistance to carbapenem had significant association with resistance to other antibiotics, which deteriorates this problem and limits options for treatment. Furthermore, high genetic diversity was observed among CRPA isolates, which necessitates constant monitoring of the molecular epidemiology of *P. aeruginosa* to detect any minor changes in the epidemiology of *P. aeruginosa* infections during the time.

Acknowledgements This study was a part of the Ph.D. thesis of Reza Heidari. The cooperation of the Department of Microbiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences is acknowledged. Our appreciation also goes to the Vice Chancellor for Research affairs, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, and Tropical and Infectious Diseases Research Center of the University for their financial (Grant No. OG-9940) and executive support.

Author contributions RH and AFS: conceptualization, methodology, writing- original draft preparation, writing-reviewing and editing, formal analysis. MH: methodology, data curation, formal analysis, writing- original draft preparation. ZF: conceptualization, data curation, formal analysis, writing-reviewing and editing. SS: conceptualization, supervision, writing-reviewing and editing. Writing- original draft preparation. MS: writing-reviewing and editing, formal analysis. All authors read and approved the final manuscript.

Funding This work was supported by the Vice Chancellor for Research affairs, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, and Tropical and Infectious Diseases Research Center of the University (Grant No. OG-9940).

Data availability All analyzed data within this study can be obtained from the corresponding author on request.

Code availability Not applicable.

Declarations

Conflict of interest The authors have no conflict of interest.

Ethical approval Ethical approval was obtained from the Ethics Committee of the Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran (IR.AJUMS.REC.1399.530). Written informed consent was obtained from all patients.

Consent to participate All patients provided written informed consent.
Consent for publication  Not applicable.

References

1. Nouri F, Karami P, Zarei O, Kosari F, Alikhani MY, Zandkarimi E et al (2020) Prevalence of common nosocomial infections and evaluation of antibiotic resistance patterns in patients with secondary infections in Hamadan. Iran Infec Drug Resist 13:2365

2. Labowsk S (2021) Pseudomonas aeruginosa as a cause of nosocomial infections. Pseudomonas aeruginosa-biofilm formation, infections and treatments IntechOpen. https://doi.org/10.5772/intechopen.9590

3. Mohammadi M, Vaisi Raiegan A, Jalali R, Ghabadi A, Salari N, Barati H (2019) The prevalence of nosocomial infections in Iranian hospitals. J Babol Uni Med Sci 21:39–45

4. Izadi N, Eshrati B, Etemad K, Mehrabi Y, Hashemi-Nazari S-S (2020) Rate of the incidence of hospital-acquired infections in Iran based on the data of the national nosocomial infections surveillance. New Microb New Infect 38:100768

5. Bogiel T, Prażyńska M, Kwiecińska-Piróg J, Mikucka A, Gospodarek-Komkovska E (2021) Carbapenem-resistant Pseudomonas aeruginosa strains-distribution of the essential enzymatic virulence factors genes. Antibiotics 10:8

6. Hu Y-Y, Cao J-M, Yang Q, Chen S, Lv H-Y, Zhou H-W et al (2019) Risk factors for carbapenem-resistant Pseudomonas aeruginosa. Zhejiang Province. China Emerg Infect Dis 25:1861

7. Yu X, Niu H, Hu T, Zhang L, Su S, He H et al (2020) High expression of Metallo-β-lactamase contributed to the resistance to carbapenem in clinical isolates of Pseudomonas aeruginosa from Baotou. China Infect Drug Resist 13:35

8. Kunwar A, Shrestha P, Shrestha S, Thapa S, Shrestha S, Amaty NM (2021) Detection of biofilm formation among Pseudomonas aeruginosa isolated from burn patients. Burns Open 5:125–129

9. Olivares E, Badel-Berchoux S, Provot C, Prévost G, Bernardi T, Jehl F (2020) Clinical impact of antibiotics for the treatment of Pseudomonas aeruginosa biofilm infections. Front Microbiol 10:2894

10. Patel C, Shah M, Singh S, Modi C, Shah P (2021) Biofilm production and antimicrobial resistance in catheter associated urinary tract infection (CAUTI) pathogens isolated from ICU patients. Eur J Mol Clin Med 8:3143–3152

11. El-Mahdy R, El-Kamishy G (2019) Virulence factors of carbapenem-resistant Pseudomonas aeruginosa in hospital-acquired infections in Mansoura. Egypt Infect Drug Resist 12:3455

12. Sawa T, Momiyama K, Mihara T, Kinuma A, Kinosita M, Moriyama K (2020) Molecular epidemiology of clinically high-risk Pseudomonas aeruginosa strains: practical overview. Microbiol Immunol 64:331–344

13. Shokhozizadeh L, Alizadeh H, Namordizadeh V, Karmostaj A (2020) Tandem repeat analysis for typing of Pseudomonas aeruginosa carrying resistance genes in southern Iran. Rev in Med Microbiol 31:92–98

14. Santos MDV, Barros MPS, Silveira-Filho VdM, Mendes-Marques CL, Lima AVA, Silva MVd et al (2021) Genetic and biochemical diversity of clinical Acinetobacter baumannii and Pseudomonas aeruginosa isolates in a public hospital in Brazil. Microb Drug Resist 27:509–517

15. Cofield CD (2020) CDC/NHS Surveillance definitions for specific types of infections.

16. Kamali E, Jamali A, Ardeblm A, Ezadi F, Mohebbi A (2020) Evaluation of antimicrobial resistance, biofilm forming potential, and the presence of biofilm-related genes among clinical isolates of Pseudomonas aeruginosa. BMC Res Notes 13:1–6

17. Rouhi S, Ramazanzadeh R, Nouri B (2019) Genotyping, pandrug resistance, extensively drug-resistant, and multi drug-resistance detection of Pseudomonas aeruginosa isolated from patients in the west of Iran. CRES J Med Biol Sci 6:170–177

18. Clinical and Laboratory Standards Institute (2020) Performance standards for antimicrobial susceptibility testing, 30 ed. CLSI supplement M100-S30. Clinical and Laboratory Standards Institute, Wayne, PA

19. Magiorakos A-P, Srinivasan A, Carey R, Carmeli Y, Falagas M, Giske C et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281

20. Duvarzani F, Saidi N, Besharati S, Saderi H, Rasooli I, Owlia P (2021) Evaluation of antibiotic resistance pattern, alginate and biofilm production in clinical isolates of Pseudomonas aeruginosa. Iran J Public Health 50:341

21. Bahador N, Shoja S, Faridi F, Dozandeh-Mobarez B, Qeshmi F, Javadvour S et al (2019) Molecular detection of virulence factors and biofilm formation in Pseudomonas aeruginosa obtained from different clinical specimens in Bandar Abbas. Iran J Microbiol 11:25

22. Vu-Thien H, Corbincue H, Fournier B, Corvol H, Clément A et al (2007) Multiple-locus variable-number tandem-repeat analysis for longitudinal survey of sources of Pseudomonas aeruginosa infection in cystic fibrosis patients. J Clin Microbiol 45:3175–3183

23. Angeletti S, Cell a E, Prosperi M, Spoto S, Fogolari M, De Florio L et al (2018) Multi-drug resistant Pseudomonas aeruginosa nosocomial strains: Molecular epidemiology and evolution. Microb Pathog 123:233–241

24. Rodulfo H, Arcia A, Hernández A, Michelli E, Martínez DdV, Guzman M et al (2019) Virulence factors and integrons are associated with MDR and XDR phenotypes in nosocomial strains of Pseudomonas aeruginosa in a Venezuelan university hospital. Rev Inst Med Trop Sao Paulo 61:e20

25. Oumeri MMQ, Yassin NA (2021) Molecular characterization of some carbapenem-resistance genes among Pseudomonas aeruginosa isolated from wound and burn infection in Duhok city, Iraq. J Duhok Uni 24:136–144

26. Gajdács M, Baráth Z, Kárpáti K, Szabó D, Usai D, Zanetti S et al (2018) Multi-drug resistant Acinetobacter baumannii carrying some carbapenem-resistance genes among Pseudomonas aerugi

27. Vaez H, Moghim S, Nasr Esfahani B, Ghasemian Safaei H (2020) Molecular epidemiology of clinically high-risk Pseudomonas aeruginosa strains-distribution of the essential enzymatic virulence factors genes. Molecular epidemiology of clinically high-risk Pseudomonas aeruginosa strains-distribution of the essential enzymatic virulence factors genes. Antibiotics 10:8

28. Motbainor H, Beredev F, Mulu W (2020) Multi-drug resistance of blood stream, urinary tract and surgical site nosocomial infections in Ethiopia: a cross-sectional study. BMC Infect Dis 20:1–11

29. Mekonnen H, Seid A, Molla G, Gebrecherkos T (2021) Antimicrobial susceptibility clinical center of Kosovo. Infect Drug Resist 12:4555

30. Lila G, Mulliqi G, Raka L, Kurti A, Bajrami R, Azizi E (2018) Molecular epidemiology of Pseudomonas aeruginosa in University clinical center of Kosovo. Infect Drug Resist 11:2039

31. Rouhi S, Ramazanzadeh R, Nouri B (2018) Prevalence of blaOxacillinase-23 and blaOxacillinase-24/40 carbapenemase genes in Pseudomonas aeruginosa isolated from patients with nosocomial and non-nosocomial infections in West of Iran. Iran J Pathol 13:348–356
32. Kresken M, Körber-Irrgang B, Korte-Berwanger M, Pfennigwerth N, Gatermann SG, Seifert H et al (2020) Dissemination of carbapenem-resistant 
\textit{Pseudomonas aeruginosa} isolates and their susceptibilities to ceftolozane-tazobactam in Germany. Int J Antimicrob Agents 55:105959

33. Hemmati H, Hasannejad-Bibalan M, Khoshdoz S, Khoshdoz P, Kaluzi TY, Ebrahim-Saraie HS et al (2020) Two years study of prevalence and antibiotic resistance pattern of Gram-negative bacteria isolated from surgical site infections in the North of Iran. BMC Res Notes 13:1–6

34. Djordjevic ZM, Folic MM, Jankovic SM (2017) Distribution and antibiotic susceptibility of pathogens isolated from adults with hospital-acquired and ventilator-associated pneumonia in intensive care unit. J Infect Public Health 10:740–744

35. Takesue Y, Watanabe A, Kusachi S, Matsumoto T, Iwamoto A, Totsuka K et al (2012) Nationwide surveillance of antimicrobial susceptibility patterns of pathogens isolated from surgical site infections (SSI) in Japan. J Infect Chemother 18:816–826

36. Voor in ’t holt AF, Severin JA, Lesaffre EM, Vos MC (2014) A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant 
\textit{Pseudomonas aeruginosa}. Antimicrob Agents Chemother 58:2626–2637

37. Rasool AA, Almohana AM, Alsehlawi ZS, Ali IA, Al-faham MAAA, Al-sherees HAA (2021) Molecular detection of carbapenem resistance genes in 
\textit{Pseudomonas aeruginosa} isolated from different hospital in najaf, Iraq. Int J Inform Res Rev 8:7242–7247

38. Cho HH, Kwon KC, Kim S, Park Y, Koo SH (2018) Association between biofilm formation and antimicrobial resistance in carbapenem-resistant 
\textit{Pseudomonas aeruginosa}. Ann Clin Lab Sci 48:363–368

39. Cepas V, López Y, Muñoz E, Rolo D, Ardanuy C, Martí S et al (2019) Relationship between biofilm formation and antimicrobial resistance in gram-negative bacteria. Microb Drug Resist 25:72–79

40. Uppe A, Gupta D, Sawant S, Nair G (2019) Incidence of biofilm formation in ET tube and correlation with occurrence of VAP in a tertiary care ICU. Am J Infect Dis 7:65–72

41. Baidya S, Sharma S, Mishra SK, Kattel HP, Parajuli K, Sherchand JB (2021) Biofilm formation by pathogens causing ventilator-associated pneumonia at intensive care units in a tertiary care hospital: an armor for refuge. BioMed Res Int 2021:8817700

42. Hosseini Doust SR, Mahmoudi Jouibari M (2018) Corelation between antibiotic resistsans and biofilm formation power of 
\textit{Pseudomonas aeruginosa}. J Pharm Health Sci 6:21–28

43. El-sayed H, Fahmy Y (2021) Correlation between biofilm formation and multidrug resistance in clinical isolates of 
\textit{Pseudomonas aeruginosa}. Microb Infect Dis 2:541–549

44. Karami P, Khaledi A, Mashoof RY, Yaghoobi MH, Karami M, Dastan D et al (2020) The correlation between biofilm formation capability and antibiotic resistance pattern in 
\textit{Pseudomonas aeruginosa}. Gene Rep 18:100561

45. Karballaei Mirzahosseini H, Hadadi-Fishani M, Morshedhi K, Khaledi A (2020) Meta-analysis of biofilm formation, antibiotic resistance pattern, and biofilm-related genes in 
\textit{Pseudomonas aeruginosa} isolated from clinical samples. Microb Drug Resist 26:815–824

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.